Log in

NASDAQ:NTRANatera Stock Price, Forecast & News

Add
Compare
Today's Range N/A
50-Day Range
$45.05
MA: $47.74
$55.17
52-Week Range N/A
Volume551,704 shs
Average Volume688,974 shs
Market Capitalization$4.16 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.32
Natera, Inc., a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora products of conception test to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid in a pregnant mother's blood and a blood sample from the alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Evercord, a cord blood and cord tissue processing and storage service; and Signatera, a circulating tumor DNA technology that analyzes and tracks mutations to an individual's tumor. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners in the United States and internationally. Natera, Inc. has research collaborations with the Institut Jules Bordet and Fox Chase Cancer Center. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.
Read More
Natera logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.4Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.75 out of 5 stars


Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NTRA
CUSIPN/A
Phone650-249-9090

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$302.33 million
Book Value$3.59 per share

Profitability

Net Income$-124,830,000.00

Miscellaneous

Employees1,039
Market Cap$4.16 billion
Next Earnings Date11/4/2020 (Estimated)
OptionableOptionable
30 days | 90 days | 365 days | Advanced Chart

Receive NTRA News and Ratings via Email

Sign-up to receive the latest news and ratings for NTRA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Natera (NASDAQ:NTRA) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Natera?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Natera in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Natera
.

When is Natera's next earnings date?

Natera is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Natera
.

How were Natera's earnings last quarter?

Natera Inc (NASDAQ:NTRA) issued its quarterly earnings results on Wednesday, August, 5th. The medical research company reported ($0.75) EPS for the quarter, missing analysts' consensus estimates of ($0.57) by $0.18. Natera had a negative net margin of 44.89% and a negative return on equity of 78.63%.
View Natera's earnings history
.

What guidance has Natera issued on next quarter's earnings?

Natera updated its FY 2020 After-Hours earnings guidance on Wednesday, August, 5th. The company provided EPS guidance of for the period. The company issued revenue guidance of $345-365 million, compared to the consensus revenue estimate of $335.5 million.

What price target have analysts set for NTRA?

8 Wall Street analysts have issued twelve-month price objectives for Natera's shares. Their forecasts range from $36.00 to $65.00. On average, they expect Natera's stock price to reach $52.25 in the next twelve months.
View analysts' price targets for Natera
.

Has Natera been receiving favorable news coverage?

Media coverage about NTRA stock has trended extremely negative this week, InfoTrie Sentiment reports. The research firm ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Natera earned a news impact score of -4.8 on InfoTrie's scale. They also gave news headlines about the medical research company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term.
View the latest news about Natera
.

Who are some of Natera's key competitors?

What other stocks do shareholders of Natera own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Natera investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Athabasca Oil (ATH), Chipotle Mexican Grill (CMG), NIC (EGOV), Aegean Marine Petroleum Network (ANW), Micron Technology (MU), Transocean (RIG) and Allergan (AGN).

Who are Natera's key executives?

Natera's management team includes the following people:
  • Dr. Matthew Rabinowitz, Co-Founder & Exec. Chairman (Age 46)
  • Mr. Steve Chapman, CEO, Pres & Director (Age 40)
  • Mr. Michael Brophy, Chief Financial Officer (Age 39)
  • Mr. Jonathan Sheena, Co-Founder, Chief Technology Officer & Director (Age 46)
  • Mr. Robert A. Schueren, Chief Operating Officer (Age 57)

When did Natera IPO?

(NTRA) raised $101 million in an IPO on Thursday, July 2nd 2015. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Morgan Stanle, Cowen and Company and Piper Jaffray served as the underwriters for the IPO and Baird and Wedbush Pacgrow were co-managers.

What is Natera's stock symbol?

Natera trades on the NASDAQ under the ticker symbol "NTRA."

Who are Natera's major shareholders?

Natera's stock is owned by a number of institutional and retail investors. Top institutional investors include Jennison Associates LLC (2.98%), Kornitzer Capital Management Inc. KS (0.82%), Frontier Capital Management Co. LLC (0.80%), Principal Financial Group Inc. (0.79%), Columbus Circle Investors (0.74%) and Granite Investment Partners LLC (0.66%). Company insiders that own Natera stock include Gail Boxer Marcus, Jonathan Sheena, Matthew Rabinowitz, Michael Burkes Brophy, Robert Alan Schueren and Steven Leonard Chapman.
View institutional ownership trends for Natera
.

Which major investors are selling Natera stock?

NTRA stock was sold by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Tygh Capital Management Inc., Chartwell Investment Partners LLC, Dupont Capital Management Corp, First Trust Advisors LP, Mutual of America Capital Management LLC, Essex Investment Management Co. LLC, and Hancock Whitney Corp. Company insiders that have sold Natera company stock in the last year include Gail Boxer Marcus, Jonathan Sheena, Matthew Rabinowitz, Michael Burkes Brophy, Robert Alan Schueren, and Steven Leonard Chapman.
View insider buying and selling activity for Natera
.

Which major investors are buying Natera stock?

NTRA stock was purchased by a variety of institutional investors in the last quarter, including Kornitzer Capital Management Inc. KS, Principal Financial Group Inc., Assenagon Asset Management S.A., Swiss National Bank, Columbus Circle Investors, Calamos Advisors LLC, Comerica Bank, and Rafferty Asset Management LLC.
View insider buying and selling activity for Natera
.

How do I buy shares of Natera?

Shares of NTRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

How big of a company is Natera?

Natera has a market capitalization of $0.00 and generates $302.33 million in revenue each year. The medical research company earns $-124,830,000.00 in net income (profit) each year or ($1.99) on an earnings per share basis. Natera employs 1,039 workers across the globe.

What is Natera's official website?

The official website for Natera is www.natera.com.

How can I contact Natera?

Natera's mailing address is 201 INDUSTRIAL ROAD SUITE 410, SAN CARLOS CA, 94070. The medical research company can be reached via phone at 650-249-9090 or via email at [email protected]

This page was last updated on 8/9/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.